<div class="container">

<table style="width: 100%;"><tr>
<td>safo</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Random generated dataset from the SAFO study</h2>

<h3>Description</h3>

<p>This dataset is a random generated dataset to reproduce the numbers needed to generate the flowchart of the SAFO study. SAFO is an open-label, multicenter, phase III–IV superiority randomized clinical trial to assess whether cloxacillin plus fosfomycin administered for the initial 7-days of therapy achieves better treatment success than cloxacillin alone in hospitalized patients with MSSA bacteremia.
</p>


<h3>Usage</h3>

<pre><code class="language-R">data(safo)
</code></pre>


<h3>Format</h3>

<p>A data frame with 925 rows and 21 columns
</p>

<dl>
<dt>id:</dt>
<dd>
<p>Identifier of each patient. This information does not match the real data.</p>
</dd>
<dt>inclusion_crit:</dt>
<dd>
<p>The patient not met the inclusion criteria?</p>
</dd>
<dt>exclusion_crit:</dt>
<dd>
<p>The patient met the exclusion criteria?</p>
</dd>
<dt>chronic_heart_failure:</dt>
<dd>
<p>Exc1: Chronic heart failure?</p>
</dd>
<dt>expected_death_24h:</dt>
<dd>
<p>Exc2: Clinical status with expected death in &lt;24h?</p>
</dd>
<dt>polymicrobial_bacteremia:</dt>
<dd>
<p>Exc3: Polymicrobial bacteremia?</p>
</dd>
<dt>conditions_affect_adhrence:</dt>
<dd>
<p>Exc4: Conditions expected to affect adhrence to the protocol?</p>
</dd>
<dt>susp_prosthetic_valve_endocard:</dt>
<dd>
<p>Exc5: Suspicion of prosthetic valve endocarditis?</p>
</dd>
<dt>severe_liver_cirrhosis:</dt>
<dd>
<p>Exc6: Severe liver cirrhosis?</p>
</dd>
<dt>acute_sars_cov2:</dt>
<dd>
<p>Exc7: Acute SARS-CoV-2 infection?</p>
</dd>
<dt>blactam_fosfomycin_hypersens:</dt>
<dd>
<p>Exc8: Beta-lactam or fosfomycin hypersensitivity?</p>
</dd>
<dt>other_clinical_trial:</dt>
<dd>
<p>Exc9: Participation in another clinical trial?</p>
</dd>
<dt>pregnancy_or_breastfeeding:</dt>
<dd>
<p>Exc10: Pregnancy or breastfeeding?</p>
</dd>
<dt>previous_participation:</dt>
<dd>
<p>Exc11: Previous participation in the SAFO trial?</p>
</dd>
<dt>myasthenia_gravis:</dt>
<dd>
<p>Exc12: Myasthenia gravis?</p>
</dd>
<dt>decline_part:</dt>
<dd>
<p>The patient declined to participate?</p>
</dd>
<dt>group:</dt>
<dd>
<p>Randomized treatment received: cloxacilin alone / cloxacilin plus fosfomycin</p>
</dd>
<dt>itt:</dt>
<dd>
<p>The patient belongs to the intention to treat (ITT) group?</p>
</dd>
<dt>reason_itt:</dt>
<dd>
<p>Reason for exclusion from the ITT group.</p>
</dd>
<dt>pp:</dt>
<dd>
<p>The patient belongs to the per protocol (PP) group?</p>
</dd>
<dt>reason_pp:</dt>
<dd>
<p>Reason for exclusion from the PP group.</p>
</dd>
</dl>
<h3>References</h3>

<p>Grillo, S., Pujol, M., Miró, J.M. et al. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial. Nat Med 29, 2518–2525 (2023). https://doi.org/10.1038/s41591-023-02569-0
</p>


</div>